Verrica Pharmaceuticals Statistics
Verrica Pharmaceuticals (1NE0) Stock Statistics & Valuation Metrics
Total Valuation
Verrica Pharmaceuticals has a market cap or net worth of EUR 54.14M. The enterprise value is EUR 121.00M.
- Market Cap
- EUR 54.14M
- Enterprise Value
- EUR 121.00M
Share Statistics
Verrica Pharmaceuticals has 17,178,785 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 17,178,785
- Owned by Insiders
- 47.73%
- Owned by Institutions
- 5.25%
Financial Efficiency
Verrica Pharmaceuticals’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -37.97%.
- Return on Equity (ROE)
- -0.72
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -37.97%
- Return on Capital Employed (ROCE)
- -0.39
- Revenue Per Employee
- 468.12K
- Profits Per Employee
- -235.34K
- Employee Count
- 76
- Asset Turnover
- 0.75
- Inventory Turnover
- 1.54
Valuation Ratios
The current PE Ratio of Verrica Pharmaceuticals is -2.02. Verrica Pharmaceuticals’s PEG ratio is -0.06.
- PE Ratio
- -2.02
- PS Ratio
- 1.99
- PB Ratio
- 17.41
- Price to FCF
- -4.53
- Price to Operating Cash Flow
- -5.62
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Verrica Pharmaceuticals had revenue of 35.58M and earned -17.89M in profits. Earnings per share was -1.68.
- Revenue
- 35.58M
- Gross Profit
- 32.14M
- Operating Income
- -11.94M
- Pretax Income
- -17.89M
- Net Income
- -17.89M
- EBITDA
- -9.36M
- Earnings Per Share (EPS)
- -1.68
Cash Flow
In the last 12 months, operating cash flow was -13.35M and capital expenditures 0, giving a free cash flow of -13.35M billion.
- Operating Cash Flow
- -13.35M
- Free Cash Flow
- -13.35M
- Free Cash Flow per Share
- -0.63
Dividends & Yields
Verrica Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -21.46%
- Earnings Yield
- -40.43%
Stock Price Statistics
- Beta
- 1.01
- 52-Week Price Change
- 6.97%
- 50-Day Moving Average
- 3.68
- 200-Day Moving Average
- 4.64
- Relative Strength Index (RSI)
- 34.69
- Average Volume (3m)
- 246
Important Dates
Verrica Pharmaceuticals upcoming earnings date is Nov 12, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Verrica Pharmaceuticals as a current ratio of 2.59, with Debt / Equity ratio of 6.59%
- Current Ratio
- 2.59
- Quick Ratio
- 2.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.05
- Interest Coverage Ratio
- -1.54
Taxes
In the past 12 months, Verrica Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Verrica Pharmaceuticals EV to EBITDA ratio is -1.98, with an EV/FCF ratio of -3.96.
- EV to Sales
- 1.74
- EV to EBITDA
- -1.98
- EV to Free Cash Flow
- -3.96
- EV to Operating Cash Flow
- -3.96
Balance Sheet
Verrica Pharmaceuticals has EUR 11.20M in cash and marketable securities with EUR 1.81M in debt, giving a net cash position of EUR 9.39M billion.
- Cash & Marketable Securities
- EUR 11.20M
- Total Debt
- EUR 1.81M
- Net Cash
- EUR 9.39M
- Net Cash Per Share
- EUR 0.55
- Tangible Book Value Per Share
- EUR 0.20
Margins
Gross margin is 85.89%, with operating margin of -92.78%, and net profit margin of -102.84%.
- Gross Margin
- 85.89%
- Operating Margin
- -92.78%
- Pretax Margin
- -102.84%
- Net Profit Margin
- -102.84%
- EBITDA Margin
- -87.98%
- EBIT Margin
- -90.53%
Analyst Forecast
The average price target for Verrica Pharmaceuticals is EUR 12.26, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 12.26
- Price Target Upside
- 289.68% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 97.22%
- EPS Growth Forecast
- 81.25%
Scores
- Smart Score
- 5
- AI Score
- ―
